Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7428-01 phase I dose escalation in advanced solid tumors
jRCT2031240647Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-7428 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability and Safety. Started Apr 2025; status: active, not recruiting.
02
Drugs
ONO-7428
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240647.